GLP-1 Lawsuit Overview
GLP-1 lawsuits involve allegations that manufacturers of medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and related drugs failed to adequately warn consumers and prescribing physicians about serious health risks associated with these medications.
GLP-1 receptor agonist drugs were originally developed to improve blood sugar control in diabetic patients, but their widespread use expanded rapidly after studies showed they could also promote weight loss.
As millions of patients began taking semaglutide and tirzepatide medications, adverse event reports involving severe gastrointestinal injuries and optic nerve complications also increased.
Plaintiffs in these lawsuits allege that some patients developed life-altering complications including gastroparesis, bowel obstruction, cyclic vomiting syndrome, gallbladder disease, pulmonary aspiration during surgery, and sudden vision loss associated with non-arteritic anterior ischemic optic neuropathy (NAION).
Many individuals who were prescribed Ozempic or similar GLP-1 medications report prolonged hospitalization, emergency medical treatment, surgical intervention, chronic digestive impairment, or permanent visual deficits following use of these drugs.
The litigation further alleges that pharmaceutical manufacturers continued aggressively marketing GLP-1 medications despite growing concerns surrounding delayed gastric emptying, intestinal motility disorders, and reported optic nerve injuries.
GLP-1 medications currently named in lawsuits include:
- Ozempic
- Wegovy
- Mounjaro
- Zepbound
- Rybelsus
- Saxenda
- Trulicity
- Victoza
- Other semaglutide and tirzepatide medications
Federal courts have established separate multidistrict litigations (MDLs) for gastrointestinal injury claims and NAION vision loss claims involving GLP-1 medications.
These proceedings allow lawsuits involving similar allegations and medical evidence to move through coordinated discovery and pretrial litigation while preserving each plaintiff’s individual claim for damages.
Plaintiffs pursuing GLP-1 lawsuits are seeking compensation for medical expenses, lost wages, pain and suffering, long-term disability, and other losses allegedly tied to severe injuries associated with these medications.
As the litigation continues to expand, additional scientific studies, regulatory reviews, and adverse event investigations may further shape the scope of GLP-1 lawsuits filed nationwide.
Which Drug Manufacturers Are Being Sued?
GLP-1 lawsuits primarily target pharmaceutical manufacturers that developed and marketed semaglutide and tirzepatide medications used for diabetes treatment and weight loss.
Plaintiffs allege that these companies failed to adequately warn consumers and prescribing physicians about severe gastrointestinal injuries, vision loss, and other reported complications associated with GLP-1 drugs.
Drug manufacturers named in GLP-1 lawsuits include:
- Novo Nordisk, manufacturer of Ozempic, Wegovy, and Rybelsus
- Eli Lilly, manufacturer of Mounjaro, Zepbound, and Trulicity
What Are GLP-1 Receptor Agonist Drugs?
GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a naturally occurring hormone involved in blood sugar regulation, digestion, and appetite control.
These drugs stimulate insulin release when blood glucose levels rise, suppress glucagon secretion, slow gastric emptying, and increase feelings of fullness after eating.
GLP-1 medications were originally developed to treat type 2 diabetes, but several drugs in this class later received FDA approval for chronic weight management and obesity treatment.
Common GLP-1 receptor agonist medications include semaglutide drugs such as Ozempic, Wegovy, and Rybelsus, as well as tirzepatide medications including Mounjaro and Zepbound.
Some GLP-1 medications are administered through weekly injections, while others are available in daily injectable or oral tablet formulations.
Although these drugs demonstrated effectiveness in improving blood sugar control and promoting weight loss, lawsuits now allege that GLP-1 receptor agonists may also be associated with severe gastrointestinal injuries, optic nerve complications, and other serious adverse health effects.
Semaglutide vs. Tirzepatide Medications
Semaglutide and tirzepatide are two different categories of incretin-based medications used to treat type 2 diabetes and obesity, although both are commonly grouped together in GLP-1 litigation.
Semaglutide medications work by activating the GLP-1 receptor alone, while tirzepatide medications activate both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, creating what is commonly described as a dual incretin mechanism.
Despite these pharmacological differences, lawsuits involving both semaglutide and tirzepatide medications allege similar gastrointestinal injuries, delayed gastric emptying complications, and other serious adverse health effects.
Off-Label Weight Loss Use and Expanding Exposure
Several GLP-1 medications were first approved for type 2 diabetes, but some patients were later prescribed off-label versions of these drugs for weight loss before separate obesity-specific formulations became available.
Off-label prescribing is legal when a licensed healthcare provider determines that a medication may be appropriate for a patient, but it can expand use beyond the exact population studied for the drug’s original FDA approval.
Demand increased sharply as semaglutide and tirzepatide medications became associated with substantial weight loss, leading more patients without diabetes to use GLP-1 drugs.
Broader use also increased the number of people potentially exposed to delayed gastric emptying, severe gastrointestinal symptoms, and other reported complications.
GLP-1 lawsuits allege that manufacturers failed to provide adequate warnings as these medications moved from diabetes treatment into widespread weight-loss use.
Health Effects Linked to GLP-1 Drugs Named in Lawsuits
GLP-1 lawsuits involve allegations that certain medications used for diabetes treatment and weight management caused serious medical conditions affecting the digestive system, gallbladder, pancreas, and optic nerve.
These drugs alter insulin signaling, digestion, and appetite suppression by slowing gastric emptying and changing how quickly food moves through the gastrointestinal tract.
Some plaintiffs allege that delayed digestion became so severe that the stomach could no longer properly process or prevent food from remaining in the digestive system for extended periods of time.
Reported injuries in GLP-1 lawsuits range from chronic nausea and vomiting to intestinal obstruction, malnutrition, emergency surgery, and sudden vision loss, with symptom severity typically ranging from temporary digestive complications to permanent impairment.
Researchers, regulators, and plaintiffs continue to examine whether dosage, duration of use, preexisting health conditions, and other factors may influence the likelihood or severity of complications associated with GLP-1 medications.
Gastroparesis (Stomach Paralysis)
Gastroparesis, commonly referred to as stomach paralysis, is a medical condition in which the stomach muscles no longer move food through the digestive tract at a normal rate.
When food remains in the stomach for extended periods of time, patients may develop severe nausea, vomiting, dehydration, malnutrition, abdominal swelling, and painful digestive complications requiring hospitalization or emergency treatment.
Severe cases of gastroparesis can also disrupt intestinal motility throughout the gastrointestinal tract, potentially contributing to constipation, bowel obstruction, or impaired movement of waste into the large intestine.
Common symptoms of gastroparesis may include:
- Severe nausea
- Vomiting undigested food
- Abdominal pain
- Bloating and abdominal swelling
- Feeling full after eating small amounts of food
- Acid reflux or heartburn
- Loss of appetite
- Dehydration
- Malnutrition
- Constipation
Bowel Obstruction and Ileus
Bowel obstruction is a condition in which the small intestine or large intestine becomes partially or completely blocked, preventing the normal movement of food, fluids, gas, and waste through the digestive tract.
Ileus is a related disorder involving impaired intestinal motility, where the muscles of the intestines stop contracting effectively even without a physical blockage.
Both conditions can cause abdominal distension, cramping, severe constipation, nausea, vomiting, dehydration, and inability to pass gas or stool.
Untreated bowel obstruction or ileus may lead to intestinal ischemia, tissue damage, perforation, infection, sepsis, and the need for emergency surgical intervention.
Cyclic Vomiting Syndrome
Cyclic vomiting syndrome is a functional gastrointestinal disorder characterized by recurrent episodes of intense nausea and frequent vomiting separated by periods of relative symptom resolution.
Episodes may last for hours or several days and can become severe enough to cause dehydration, electrolyte imbalance, esophageal irritation, malnutrition, and repeated hospitalization.
Patients experiencing cyclic vomiting syndrome often report abdominal pain, inability to tolerate food or liquids, dizziness, fatigue, and metabolic complications associated with prolonged vomiting.
Pancreatitis
Pancreatitis is an inflammatory condition involving the pancreas, an organ responsible for producing digestive enzymes and regulating blood sugar through insulin secretion.
Acute pancreatitis can cause severe upper abdominal pain, persistent vomiting, fever, elevated pancreatic enzymes, tissue necrosis, infection, and, in severe cases, organ failure requiring intensive medical treatment.
Prescribing information for several GLP-1 receptor agonist medications includes warnings regarding acute pancreatitis, including hemorrhagic and necrotizing forms of pancreatic inflammation reported during clinical use and post-market surveillance.
Researchers have also continued to examine whether chronic pancreatic inflammation, recurrent pancreatitis, or prolonged pancreatic injury could contribute to long-term complications involving pancreatic cancer, although current evidence regarding causation remains under ongoing scientific review.
Pulmonary Aspiration During Surgery or Anesthesia
Pulmonary aspiration occurs when stomach contents enter the lungs or airways during general anesthesia, deep sedation, or other medical procedures that impair normal protective reflexes.
Because GLP-1 receptor agonist medications slow gastric emptying, some patients may retain significant amounts of food or fluid in the stomach even after standard preoperative fasting periods.
Residual gastric contents can increase the risk of regurgitation, aspiration pneumonia, respiratory distress, lung inflammation, or other serious perioperative complications during surgery or endoscopic procedures.
In response to growing concern surrounding delayed gastric emptying and aspiration risk, anesthesia societies and regulatory agencies have issued updated guidance addressing perioperative management of patients taking semaglutide and tirzepatide medications.
Patients experiencing severe nausea, vomiting, abdominal distension, or known gastroparesis before surgery may require individualized anesthesia planning, delayed procedures, modified fasting instructions, or additional airway precautions to reduce aspiration risk.
Malnutrition and Severe Dehydration
Malnutrition and severe dehydration can develop when persistent nausea, vomiting, delayed gastric emptying, or intestinal dysfunction interfere with normal food and fluid intake.
Prolonged digestive impairment may prevent adequate absorption of calories, vitamins, minerals, electrolytes, and protein needed to maintain normal metabolic function and body weight.
Severe dehydration can lead to dizziness, weakness, kidney injury, low blood pressure, electrolyte imbalance, cardiac complications, and hospitalization requiring intravenous fluids or nutritional support.
Patients with chronic gastrointestinal symptoms may also experience rapid weight loss, muscle wasting, fatigue, and worsening nutritional deficiencies over time.
Vision Loss and NAION
Non-arteritic anterior ischemic optic neuropathy (NAION) is a serious optic nerve condition sometimes referred to as an “eye stroke” because it occurs when reduced blood flow damages the optic nerve.
NAION typically causes sudden, painless vision loss in one eye and may result in permanent visual impairment, blind spots, reduced peripheral vision, or loss of visual clarity.
A 2024 study found that patients taking semaglutide medications were significantly more likely to develop NAION compared to certain other diabetes medications, raising concern about a possible association between GLP-1 drugs and optic nerve injury.
Researchers and regulatory agencies continue to evaluate the relationship between semaglutide use, optic nerve ischemia, and long-term vision complications as additional clinical data and adverse event reports emerge.
Symptoms associated with NAION may include:
- Sudden vision loss
- Blurred or dimmed vision
- Loss of peripheral vision
- Blind spots or darkened visual fields
- Reduced color perception
- Optic nerve swelling
- Permanent visual impairment
Current Status of the GLP-1 MDLs
Federal GLP-1 litigation is currently divided into two separate multidistrict litigations (MDLs) in the Eastern District of Pennsylvania, where lawsuits involving similar allegations and scientific evidence are being coordinated before a single federal judge.
One MDL focuses on gastrointestinal injuries such as gastroparesis, bowel obstruction, ileus, and severe vomiting, while the second MDL involves claims alleging semaglutide medications caused non-arteritic anterior ischemic optic neuropathy (NAION) and permanent vision loss.
MDLs are designed to streamline the legal process for large numbers of plaintiffs filing lawsuits involving common factual questions, shared medical evidence, and overlapping allegations against pharmaceutical manufacturers.
These proceedings allow the parties to conduct coordinated discovery, exchange internal company documents, depose medical experts, and litigate pretrial issues without requiring every case to proceed independently through separate federal courts.
The litigation continues to evolve as additional plaintiffs file claims involving GLP-1 medications manufactured by Novo Nordisk and Eli Lilly, including Ozempic, Wegovy, Mounjaro, Zepbound, and related drugs.
Ongoing scientific research, regulatory developments, expert testimony, and bellwether case preparation are expected to shape how the GLP-1 MDLs develop moving forward.
Who May Qualify for a GLP-1 Lawsuit?
Individuals who developed serious gastrointestinal complications, diagnosed optic nerve injuries, or other severe side effects after taking GLP-1 receptor agonist medications may qualify to pursue legal action.
Potential claims generally involve medications containing the active ingredient semaglutide or tirzepatide, including Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound.
Many cases involve patients who required hospitalization, emergency medical treatment, surgery, specialist care, or long-term treatment after developing digestive disorders or sudden vision problems.
Medical records, prescription history, diagnostic testing, and physician evaluations are often used to determine whether a person may have a viable claim connected to GLP-1 medication use.
Patients who experienced symptoms shortly after beginning treatment, increasing dosage, or prolonged use of these medications may also be evaluated for potential eligibility.
Because every case involves different medical history, risk factors, and treatment timelines, medical professionals and legal counsel typically review claims individually to assess the strength of the supporting evidence.
Factors that may support a GLP-1 lawsuit claim include:
- Use of Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or another GLP-1 medication
- Diagnosed gastroparesis, bowel obstruction, ileus, NAION, or other serious complications
- Hospitalization, emergency treatment, or surgery related to symptoms
- Persistent nausea, vomiting, abdominal pain, or sudden vision changes
- Medical imaging, gastric emptying studies, ophthalmologic testing, or specialist evaluations
- Documented prescription history and treatment timeline
- Long-term digestive impairment or permanent vision loss
Evidence Used in GLP-1 Cases
Medical evidence often plays a central role in determining whether a patient may have a viable GLP-1 lawsuit claim involving gastrointestinal injuries, vision loss, or other serious complications.
Records documenting symptoms, diagnosis, treatment history, and the timing of medication use can help establish whether complications developed after exposure to semaglutide or tirzepatide medications.
Patients who sought medical attention for severe nausea, vomiting, abdominal pain, bowel obstruction, sudden vision changes, or optic nerve injuries may already possess important medical documentation connected to their claim.
A legal team handling GLP-1 litigation can help gather, preserve, organize, and review relevant evidence, including medical records showing diagnoses, imaging findings, specialist evaluations, prescription history, and treatment progression.
Evidence commonly used in GLP-1 cases may include:
- Medical records showing diagnosed gastroparesis, bowel obstruction, ileus, NAION, pancreatitis, or related complications
- Prescription and pharmacy records documenting GLP-1 medication use
- Gastric emptying studies
- CT scans, abdominal imaging, and endoscopy records
- Hospitalization and emergency room records
- Ophthalmology records and optic nerve testing
- Surgical records and operative reports
- Laboratory testing and bloodwork
- Physician notes and specialist evaluations
- Documentation of ongoing symptoms and long-term complications
What Compensation May Be Available in a GLP-1 Lawsuit?
Compensation in GLP-1 lawsuits may depend on the severity of the injury, the extent of medical treatment required, the permanence of the condition, and the overall impact the complications had on a person’s daily life and ability to work.
Individuals diagnosed with gastroparesis, bowel obstruction, NAION, pancreatitis, or other serious complications may pursue damages connected to hospitalization, surgery, long-term treatment, and ongoing medical care.
Lawyers handling GLP-1 litigation often work with physicians, economic experts, and other specialists to assess the full financial and personal impact of an injury, including future medical needs and long-term disability.
A law firm may also help calculate losses tied to medical expenses, lost earnings, physical pain and suffering, emotional distress, and reduced quality of life resulting from severe complications associated with GLP-1 medications.
Compensation potentially available in a GLP-1 lawsuit may include:
- Past and future medical expenses
- Hospitalization and surgical costs
- Lost wages and lost earning capacity
- Physical pain and suffering
- Emotional distress
- Long-term disability or permanent impairment
- Costs associated with vision loss or digestive impairment
- Rehabilitation and specialist treatment expenses
- Loss of quality of life
- Wrongful death damages in fatal cases
TorHoerman Law: Reviewing GLP-1 Lawsuit Claims Nationwide
TorHoerman Law is actively reviewing GLP-1 lawsuit claims involving severe gastrointestinal injuries, NAION-related vision loss, bowel obstruction, gastroparesis, pancreatitis, and other serious complications associated with semaglutide and tirzepatide medications.
Our legal team conducts a thorough investigation of each claim by reviewing prescription history, diagnostic testing, hospitalization records, specialist evaluations, and other medical evidence connected to the reported injury.
TorHoerman Law has a proven track record handling complex pharmaceutical and mass tort litigation involving defective drugs, dangerous medical products, and large-scale injury claims against major corporations.
We accept GLP-1 lawsuits on a contingency fee basis, meaning there are no upfront costs and clients do not pay attorney fees unless compensation is recovered through settlement or litigation.
If you or a loved one suffered severe complications after taking Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or another GLP-1 medication, contact TorHoerman Law for a free case review to learn more about your legal options.
You can also use the chat feature on this page to find out if you qualify for the GLP-1 lawsuit.
